Healthcare / BiotechnologyTokyo
$4560.00
-395.00 (-7.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-487.0M · quality 55.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$37.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-11.7%
↓Gross Margin
96.0%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+132.7%
FCF CAGR
—
FCF margin
-515.1%
FCF / Net income
1.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $175.2M · net income $-644.3M · FCF $-902.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $175.2M | $175.2M | $23.1M | $38.3M | $13.9M |
| Net Income | $-644.3M | $-644.3M | $-632.2M | $-452.1M | $-375.3M |
| EBITDA | $-513.6M | $-513.6M | $-518.4M | $-371.8M | $-280.4M |
| EPS | -80.52 | -80.52 | -85.86 | -59.94 | -49.76 |
| Gross Margin | 96.0% | 96.0% | 41.7% | 54.9% | 76.6% |
| Operating Margin | -336.9% | -336.9% | -2547.3% | -1176.7% | -2682.9% |
| Net Margin | -367.8% | -367.8% | -2736.5% | -1181.0% | -2697.7% |
| Balance Sheet | |||||
| Current Ratio | 15.96 | 15.96 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-902.5M | $-902.5M | $-487.0M | $-412.2M | $-249.5M |
| Returns | |||||
| ROE | -11.7% | -11.7% | -10.6% | -13.1% | -9.6% |
| Valuation | |||||
| P/B | 6.60 | 6.60 | 4.62 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 658.4% | 658.4% | -39.6% | 175.1% | — |
| EPS Growth | 6.2% | 6.2% | -43.2% | -20.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-28.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-85.86 → -80.52
Residual
-28.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.